New dosing strategy aims to reduce eye damage from myeloma drug
NCT ID NCT05847569
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial is testing different doses and schedules of belantamab mafodotin, a drug that delivers chemotherapy directly to myeloma cells. The goal is to find a way to give the drug that causes fewer severe eye problems while still controlling the cancer. About 62 adults with multiple myeloma that has returned or stopped responding to other treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belantamab mafodotin (a targeted antibody-drug combination)
What this could lead to
If successful, this could lead to a safer dosing approach for belantamab mafodotin, reducing severe eye side effects while still controlling multiple myeloma.
What could go wrong
This is a small, early-phase trial (62 participants) testing different doses, not a cure. The drug may still cause side effects or not work well enough for broader use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact